ATNF Valuation

180 Life Sciences Corp

Add to Watchlist

Advanced Chart

7.300

+0.26(3.693%)1D

Overview
Forecast
Valuation
Earnings

ATNF Relative Valuation

ATNF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATNF is overvalued; if below, it's undervalued.

Historical Valuation

180 Life Sciences Corp (ATNF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.36 is considered Undervalued compared with the five-year average of -19.00. The fair price of 180 Life Sciences Corp (ATNF) is between 58.50 to 61.16 according to relative valuation methord. Compared to the current price of 7.30 USD , 180 Life Sciences Corp is Undervalued By 87.52%.

Relative Value

Fair Zone

58.50-61.16

Current Price：7.30

87.52%

Undervalued

-0.01

Trailing

Forward

0.00

EV/EBITDA

180 Life Sciences Corp. (ATNF) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.27

EV/EBIT

180 Life Sciences Corp. (ATNF) has a current EV/EBIT of -0.27. The 5-year average EV/EBIT is -3.23. The thresholds are as follows: Strongly Undervalued below -13.72, Undervalued between -13.72 and -8.48, Fairly Valued between 2.01 and -8.48, Overvalued between 2.01 and 7.25, and Strongly Overvalued above 7.25. The current Forward EV/EBIT of -0.27 falls within the Historic Trend Line -Fairly Valued range.

0.36

180 Life Sciences Corp. (ATNF) has a current PS of 0.36. The 5-year average PS is 3.40. The thresholds are as follows: Strongly Undervalued below -18.69, Undervalued between -18.69 and -7.64, Fairly Valued between 14.44 and -7.64, Overvalued between 14.44 and 25.49, and Strongly Overvalued above 25.49. The current Forward PS of 0.36 falls within the Historic Trend Line -Fairly Valued range.

-0.74

P/OCF

180 Life Sciences Corp. (ATNF) has a current P/OCF of -0.74. The 5-year average P/OCF is -0.89. The thresholds are as follows: Strongly Undervalued below -5.09, Undervalued between -5.09 and -2.99, Fairly Valued between 1.20 and -2.99, Overvalued between 1.20 and 3.30, and Strongly Overvalued above 3.30. The current Forward P/OCF of -0.74 falls within the Historic Trend Line -Fairly Valued range.

-0.49

P/FCF

180 Life Sciences Corp. (ATNF) has a current P/FCF of -0.49. The 5-year average P/FCF is -2.98. The thresholds are as follows: Strongly Undervalued below -13.74, Undervalued between -13.74 and -8.36, Fairly Valued between 2.40 and -8.36, Overvalued between 2.40 and 7.78, and Strongly Overvalued above 7.78. The current Forward P/FCF of -0.49 falls within the Historic Trend Line -Fairly Valued range.

180 Life Sciences Corp (ATNF) has a current Price-to-Book (P/B) ratio of 0.71. Compared to its 3-year average P/B ratio of -3.27 , the current P/B ratio is approximately -121.81% higher. Relative to its 5-year average P/B ratio of 5.17, the current P/B ratio is about -86.20% higher. 180 Life Sciences Corp (ATNF) has a Forward Free Cash Flow (FCF) yield of approximately -21.96%. Compared to its 3-year average FCF yield of -254.92%, the current FCF yield is approximately -91.38% lower. Relative to its 5-year average FCF yield of -160.92% , the current FCF yield is about -86.35% lower.

0.71

P/B

Median3y

-3.27

Median5y

5.17

-21.96

FCF Yield

Median3y

-254.92

Median5y

-160.92

Competitors Valuation Multiple

The average P/S ratio for ATNF's competitors is 11.91, providing a benchmark for relative valuation. 180 Life Sciences Corp Corp (ATNF) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ATNF.O

180 Life Sciences Corp

Pasithea Therapeutics Corp

China Pharma Holdings Inc

Indaptus Therapeutics Inc

Performance Decomposition

Market capitalization of ATNF increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ATNF in the past 1 year is driven by Unknown.